insights_auto
Pourquoi BVNRY a-t-elle augmenté de 2,62%?
Approfondirchevron_right
BVNRY:OTCMKTS
Bavarian Nordic
11,37 $US
arrow_upward
+2,62%(+0,29) 1J
6 oct., 09:30:04 UTC−4 · USD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour BVNRY...
Ouverture
11,37 $US
Élevé
11,37 $US
Faible
11,37 $US
Cap. boursière
2,65 Md
Vol. moyen
2,64 k
Volume
467,00
Ratio cours/bénéfice
12,19
+ haut sur 1 an
13,00 $US
+ bas sur 1 an
8,67 $US
BPA
0,93 $US
Bêta
1,45
Actions en circulation
237,82 M
Nombre d'employés
2 k
Ouverture
11,37 $US
Élevé
11,37 $US
Faible
11,37 $US
Cap. boursière
2,65 Md
Vol. moyen
2,64 k
Volume
467,00
Ratio cours/bénéfice
12,19
+ haut sur 1 an
13,00 $US
+ bas sur 1 an
8,67 $US
BPA
0,93 $US
Bêta
1,45
Actions en circulation
237,82 M
Nombre d'employés
2 k
Articles
Sources : Web et partenaires du secteur de l'information
GlobeNewswire
·
il y a 1 jour
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profil
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
À propos de Bavarian Nordic
PDGPaul Chaplin
Employés1,91 k
Date de création1 juil. 1992
Siège social-
Secteur-
Site Webbavarian-nordic.com